Granisetron Fresenius Kabi
5-HT3 receptor antagonist for the prevention and treatment of chemotherapy-induced nausea and vomiting
Granisetron Fresenius Kabi is a prescription antiemetic medication containing granisetron, a selective 5-HT3 (serotonin type 3) receptor antagonist. Administered intravenously, it is used to prevent and treat nausea and vomiting caused by chemotherapy, radiotherapy, and surgery in adults and children aged 2 years and older. This medication works by blocking the action of serotonin at specific receptor sites in the brain and gut, effectively suppressing the vomiting reflex. It is widely recommended by international oncology guidelines as a cornerstone of antiemetic therapy.
Quick Facts
Key Takeaways
- Granisetron Fresenius Kabi is a potent 5-HT3 receptor antagonist used to prevent and treat chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea, and post-operative nausea and vomiting (PONV).
- It is administered intravenously by a healthcare professional, with doses typically ranging from 1 to 3 mg for adults, and weight-based dosing (10-40 mcg/kg) for children aged 2 years and older.
- The most common side effects are headache and constipation; serious but rare side effects include serotonin syndrome and QT interval prolongation on ECG.
- It should not be combined with other 5-HT3 antagonists and requires caution when used alongside serotonergic medications such as SSRIs and SNRIs.
- Corticosteroids such as dexamethasone are frequently co-administered to enhance the antiemetic effect, as recommended by MASCC/ESMO guidelines.
What Is Granisetron Fresenius Kabi and What Is It Used For?
Granisetron Fresenius Kabi contains the active substance granisetron, which belongs to a class of medicines known as 5-HT3 receptor antagonists or antiemetics (medicines that prevent nausea and vomiting). It is manufactured by Fresenius Kabi, a global healthcare company specializing in injectable pharmaceuticals and clinical nutrition.
Nausea and vomiting are among the most distressing side effects of cancer treatment. Cytotoxic chemotherapy drugs damage cells in the gastrointestinal tract, triggering the release of large amounts of serotonin (5-hydroxytryptamine, or 5-HT). This serotonin activates 5-HT3 receptors on vagal afferent nerves in the gut wall and in the chemoreceptor trigger zone (CTZ) of the brain, initiating the vomiting reflex. Granisetron works by selectively and competitively blocking these 5-HT3 receptors, thereby interrupting the signaling pathway that causes emesis.
The medication is clinically indicated for three primary uses. First, it is used for the prevention of chemotherapy-induced nausea and vomiting (CINV), which can be acute (occurring within 24 hours of treatment) or delayed (occurring 24 hours to 5 days after treatment). Second, it provides prophylaxis and treatment of radiotherapy-induced nausea and vomiting, particularly in patients receiving total body irradiation or abdominal radiation. Third, it is effective for the prevention and treatment of post-operative nausea and vomiting (PONV), a common complication following general anaesthesia.
According to the Multinational Association of Supportive Care in Cancer (MASCC) and the European Society for Medical Oncology (ESMO), 5-HT3 receptor antagonists like granisetron are a fundamental component of antiemetic regimens for patients receiving moderate to highly emetogenic chemotherapy. The MASCC/ESMO guidelines recommend their use in combination with corticosteroids and, for highly emetogenic regimens, with NK1 receptor antagonists.
Granisetron Fresenius Kabi is supplied as a clear, colourless solution for injection at a concentration of 1 mg/ml. It is available in ampoules of 1 ml (containing 1 mg granisetron) and 3 ml (containing 3 mg granisetron). The solution is intended for intravenous use only and is approved for use in adults and children aged 2 years and older for chemotherapy- and radiotherapy-related indications.
What Should You Know Before Receiving Granisetron Fresenius Kabi?
Before receiving Granisetron Fresenius Kabi, it is essential to discuss your complete medical history and current medications with your healthcare provider. Certain conditions and drug combinations may affect the safety and efficacy of this medication. Your doctor or nurse will perform a thorough assessment to determine whether granisetron is appropriate for you.
Contraindications
Do not use Granisetron Fresenius Kabi if you are allergic (hypersensitive) to granisetron or to any of the other ingredients listed in the composition section of this guide. Allergic reactions to 5-HT3 receptor antagonists, while rare, can be serious and may include anaphylaxis. Cross-sensitivity between different 5-HT3 antagonists has been reported in the medical literature, so patients with a known allergy to ondansetron or dolasetron should exercise particular caution.
Warnings and Precautions
Talk to your doctor, pharmacist, or nurse before receiving Granisetron Fresenius Kabi if any of the following apply to you:
- Intestinal obstruction: If you have problems with bowel movements due to a blockage in the intestines (subacute intestinal obstruction), granisetron may mask the symptoms of an underlying condition. Your doctor should investigate any unexplained abdominal symptoms before and during treatment.
- Cardiac conditions: If you have heart problems, are being treated with cardiotoxic anticancer drugs, or have electrolyte imbalances (particularly low levels of potassium, sodium, or calcium), your doctor will monitor you carefully. Granisetron and other 5-HT3 antagonists have been associated with changes in the electrical activity of the heart, including QT interval prolongation, which may lead to abnormal heart rhythms.
- Concurrent 5-HT3 antagonist use: Do not use Granisetron Fresenius Kabi simultaneously with other 5-HT3 receptor antagonists such as ondansetron or dolasetron. Combining these drugs does not enhance efficacy but may increase the risk of adverse effects, including cardiac events.
Serotonin syndrome is an uncommon but potentially life-threatening reaction that may occur with granisetron use. The risk is significantly increased when granisetron is taken together with serotonergic medications, particularly selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, or escitalopram, and serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine or duloxetine. Symptoms include agitation, confusion, hallucinations, rapid heartbeat, blood pressure fluctuations, fever, excessive sweating, muscle rigidity, tremor, and loss of coordination. Seek immediate medical attention if any of these symptoms develop.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor before receiving this medicine. There is limited data on the use of granisetron in pregnant women. Animal studies have not demonstrated direct harmful effects on fertility or foetal development at clinically relevant doses; however, as a precautionary measure, granisetron should only be used during pregnancy when the potential benefit justifies the potential risk to the foetus.
It is not known whether granisetron is excreted in human breast milk. A decision must be made whether to discontinue breastfeeding or to withhold granisetron, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. If you are undergoing chemotherapy, the decision will typically be guided by the overall oncology treatment plan.
Driving and Operating Machinery
Granisetron Fresenius Kabi is not expected to impair your ability to drive or use machines. However, as with any medication administered in a clinical setting, you should be aware of your general condition and any side effects such as headache or dizziness before engaging in activities that require alertness. The underlying cancer treatment and overall clinical status may also affect your ability to drive safely.
This medicine contains less than 1 mmol (23 mg) sodium per ampoule, which means it is essentially sodium-free. This is relevant for patients on controlled sodium diets or those receiving multiple intravenous medications that may collectively contribute to sodium intake.
How Does Granisetron Fresenius Kabi Interact with Other Drugs?
Drug interactions can alter how a medicine works or increase the risk of serious side effects. It is vital that your healthcare team is fully informed of all medications you are taking. Granisetron is primarily metabolized in the liver by cytochrome P450 enzymes (particularly CYP3A4), which means that drugs affecting these enzyme pathways may alter granisetron levels in the body.
The following table summarizes the most clinically significant interactions with Granisetron Fresenius Kabi. This is not an exhaustive list, and your doctor should be consulted about any potential interactions with other medicines you are taking.
Major Interactions
| Interacting Drug | Drug Class | Interaction Effect | Clinical Action |
|---|---|---|---|
| Ondansetron, Dolasetron | 5-HT3 Antagonists | Increased risk of cardiac QT prolongation and serotonin syndrome | Avoid concomitant use |
| Fluoxetine, Paroxetine, Sertraline, Fluvoxamine, Citalopram, Escitalopram | SSRIs | Increased risk of serotonin syndrome | Monitor closely for serotonin syndrome symptoms |
| Venlafaxine, Duloxetine | SNRIs | Increased risk of serotonin syndrome | Monitor closely for serotonin syndrome symptoms |
| Antiarrhythmic agents (e.g., amiodarone, sotalol) | Cardiac drugs | Additive QT prolongation risk | ECG monitoring recommended |
Pharmacokinetic Interactions
| Interacting Drug | Mechanism | Effect on Granisetron | Clinical Action |
|---|---|---|---|
| Phenobarbital | CYP3A4 enzyme inducer | May reduce granisetron plasma levels | Dose adjustment may be needed |
| Ketoconazole | CYP3A4 enzyme inhibitor | May increase granisetron plasma levels | Monitor for increased side effects |
| Erythromycin | CYP3A4 enzyme inhibitor | May increase granisetron plasma levels | Monitor for increased side effects |
Granisetron does not appear to inhibit or induce the cytochrome P450 enzyme system to a clinically significant degree, meaning it is unlikely to affect the metabolism of most other drugs. However, because it is partially metabolized by CYP3A4, strong inducers such as phenobarbital, rifampicin, and carbamazepine may accelerate its clearance, potentially reducing its antiemetic efficacy. Conversely, potent CYP3A4 inhibitors such as ketoconazole and erythromycin may increase granisetron plasma concentrations, although clinical studies suggest these changes are generally modest and well tolerated.
It is important to note that chemotherapy regimens themselves often include multiple drugs with overlapping toxicity profiles. Your oncology team will carefully select your antiemetic protocol to minimize the risk of harmful interactions while maximizing nausea control.
What Is the Correct Dosage of Granisetron Fresenius Kabi?
Granisetron Fresenius Kabi will always be administered by a doctor, nurse, or other qualified healthcare professional. The dose varies from patient to patient depending on age, weight, the clinical indication, and whether the medication is being given for prevention (prophylaxis) or treatment of established nausea and vomiting. The solution is given intravenously, either as a direct injection over 30 seconds to 5 minutes, or as a diluted infusion over 5 minutes.
Adults
Prevention of Chemotherapy/Radiotherapy-Induced Nausea and Vomiting
A dose of 1 to 3 mg is administered by slow intravenous injection (over 30 seconds to 5 minutes) or by intravenous infusion (diluted and given over 5 minutes). The injection is given before the start of chemotherapy or radiotherapy. The solution must be diluted before injection (1 ml ampoule diluted to 5 ml; 3 ml ampoule diluted to 15 ml) or infusion (diluted in 20-50 ml of compatible fluid).
Treatment of Established CINV
A dose of 1 to 3 mg is given as an intravenous injection or infusion. Additional doses may be administered if nausea or vomiting persists, with a minimum interval of 10 minutes between doses. The maximum daily dose is 9 mg.
Post-Operative Nausea and Vomiting (PONV)
A single dose of 1 mg is given as a slow intravenous injection (over 30 seconds to 5 minutes). The maximum daily dose for PONV is 3 mg.
Combination with Corticosteroids
The efficacy of granisetron may be enhanced by co-administration of corticosteroids. Options include dexamethasone 8-20 mg given intravenously before chemotherapy or radiotherapy, or methylprednisolone 250 mg given before and after treatment. This combination is recommended by MASCC/ESMO guidelines for both moderately and highly emetogenic chemotherapy regimens.
Children (Aged 2 Years and Older)
For the prevention and treatment of chemotherapy- and radiotherapy-induced nausea and vomiting, children receive a weight-based dose. The recommended dose is 10 to 40 micrograms per kilogram of body weight (mcg/kg), administered as an intravenous infusion diluted in 10-30 ml of compatible fluid and given over 5 minutes before the start of treatment. A maximum of two doses per day may be given, with at least 10 minutes between doses.
Granisetron Fresenius Kabi injection is not approved for the prevention or treatment of post-operative nausea and vomiting (PONV) in children. Only chemotherapy- and radiotherapy-related indications are authorized in the paediatric population.
Elderly Patients
No specific dose adjustments are required for elderly patients. However, as older adults are more likely to have underlying cardiac conditions, electrolyte disturbances, and polypharmacy, careful monitoring is advisable. The healthcare team should consider the patient's overall clinical status, renal function, and other medications when determining the appropriate dose.
Missed Dose
Since Granisetron Fresenius Kabi is administered by healthcare professionals in a clinical setting, missed doses are unlikely. If a scheduled prophylactic dose is not given before chemotherapy or radiotherapy, the healthcare team will administer it as soon as the omission is identified, provided the treatment session has not yet concluded.
Overdose
Because this medication is given by trained medical professionals, the risk of overdose is very low. In the event of an accidental overdose, the most commonly reported symptom is mild headache. There is no specific antidote for granisetron. Treatment of overdose is supportive and symptomatic. In clinical trials, single doses up to 38.5 mcg/kg have been administered without significant adverse effects beyond those seen at standard doses. ECG monitoring is recommended in cases of significant overdose due to the theoretical risk of QT prolongation.
| Patient Group | Indication | Dose | Max Daily Dose |
|---|---|---|---|
| Adults | CINV Prevention/Treatment | 1-3 mg IV | 9 mg |
| Adults | PONV Prevention/Treatment | 1 mg IV | 3 mg |
| Children (≥2 years) | CINV Prevention/Treatment | 10-40 mcg/kg IV | 2 doses/day |
| Children | PONV | Not recommended | N/A |
| Elderly | All indications | Same as adults | Same as adults |
What Are the Side Effects of Granisetron Fresenius Kabi?
Like all medicines, Granisetron Fresenius Kabi can cause side effects, although not everybody experiences them. Most side effects are mild to moderate and resolve without intervention. However, some side effects require immediate medical attention. Understanding the frequency and nature of these effects can help you and your healthcare team manage them effectively.
If you experience any signs of a severe allergic reaction (anaphylaxis) such as swelling of the throat, face, lips, or mouth, difficulty breathing or swallowing, or sudden skin rash with itching, seek emergency medical care immediately. Although extremely rare, anaphylaxis can be life-threatening and requires prompt treatment with epinephrine.
The following side effects have been reported with granisetron use. They are organized by frequency according to the international MedDRA classification system used by regulatory agencies including the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).
Very Common
Affects more than 1 in 10 people
- Headache — the most frequently reported side effect; usually mild and self-limiting. Can often be managed with standard analgesics such as paracetamol (acetaminophen).
- Constipation — may require dietary measures (increased fibre and fluid intake) or laxatives if persistent. Your doctor will assess this, particularly in patients already experiencing chemotherapy-related bowel changes.
Common
Affects 1 in 10 to 1 in 100 people
- Insomnia — difficulty sleeping, which may be related to the overall stress of cancer treatment and hospitalization as well as the medication itself.
- Diarrhea — usually mild and transient; adequate hydration is important, especially in patients concurrently receiving chemotherapy.
- Liver function changes — elevated transaminase levels (AST, ALT) detected on blood tests. These are typically transient and asymptomatic, resolving spontaneously. Your doctor will monitor liver function through routine blood work.
Uncommon
Affects 1 in 100 to 1 in 1,000 people
- Skin rash, allergic skin reactions, or urticaria (hives) — signs may include red, raised, itchy patches on the skin. Mild reactions may be managed with antihistamines, but more severe reactions require medical evaluation.
- Cardiac rhythm changes and ECG abnormalities — including QT interval prolongation. This is more likely in patients with pre-existing cardiac conditions, electrolyte abnormalities, or those taking other QT-prolonging medications.
- Extrapyramidal symptoms — abnormal involuntary movements such as tremors, muscle stiffness, and muscle contractions (dystonia). These are generally transient and resolve after treatment discontinuation.
- Serotonin syndrome — symptoms may include diarrhea, nausea, vomiting, fever, high blood pressure, excessive sweating, rapid heart rate, agitation, confusion, hallucinations, shivering, muscle twitching, tremor, rigidity, loss of coordination, and restlessness. This is most likely when granisetron is combined with other serotonergic medications.
Reporting Side Effects
If you experience any side effects, including those not listed in this guide, talk to your doctor, pharmacist, or nurse. Reporting suspected adverse reactions after a medicine has been authorized is important for ongoing safety monitoring. In the European Union, you can report side effects through your national medicines agency. In the United States, adverse events can be reported to the FDA MedWatch programme. In the United Kingdom, reports can be made through the Yellow Card Scheme operated by the MHRA.
By reporting side effects, you help provide more information on the benefit-risk balance of medicines, contributing to the safety of all patients who receive these treatments.
How Should Granisetron Fresenius Kabi Be Stored?
Proper storage of pharmaceutical products is essential to maintain their efficacy and safety. Granisetron Fresenius Kabi should be stored according to the following guidelines, which apply primarily to healthcare facilities where the product is handled:
- Keep out of the sight and reach of children at all times.
- Do not use after the expiry date printed on the carton and ampoule label. The expiry date refers to the last day of the stated month.
- Store in the outer carton to protect the solution from light. Granisetron is light-sensitive and exposure to prolonged light may affect its stability.
- Do not freeze. Freezing may alter the physical properties of the solution and is not permitted.
- Once opened, use immediately. The ampoules are single-use containers; any unused solution remaining in an opened ampoule must be discarded.
- After dilution, the prepared solution should ideally be used immediately. If not used immediately, it may be stored at room temperature (25°C), protected from direct sunlight, and must be used within 24 hours. Diluted solutions that have been stored must be prepared using appropriate aseptic techniques.
The shelf life of unopened ampoules is 3 years from the date of manufacture when stored under the recommended conditions. Granisetron Fresenius Kabi is compatible for dilution with 0.9% sodium chloride injection, 5% glucose injection, and Ringer-lactate solution. No other diluent solutions should be used. As a general precaution, granisetron should not be mixed with other medications in the same infusion bag or syringe.
Granisetron Fresenius Kabi 1 mg/ml is compatible with dexamethasone dihydrogen phosphate disodium at concentrations of 10-60 mcg/ml granisetron and 80-480 mcg/ml dexamethasone phosphate, diluted in 0.9% sodium chloride or 5% glucose, and remains stable for up to 24 hours. This compatibility is clinically relevant as the two drugs are frequently co-administered.
Unused medicines should not be disposed of via wastewater or household waste. Follow local regulations for the disposal of pharmaceutical waste. Healthcare facilities typically have dedicated procedures for the safe disposal of cytotoxic and pharmaceutical waste in compliance with environmental protection regulations.
What Does Granisetron Fresenius Kabi Contain?
Understanding the full composition of a medicine is important for identifying potential allergens and ensuring compatibility with other treatments. Granisetron Fresenius Kabi is a sterile, preservative-free solution designed exclusively for intravenous administration.
Active Ingredient
The active substance is granisetron, present as granisetron hydrochloride. Each millilitre of the solution for injection contains 1 mg of granisetron (equivalent to approximately 1.12 mg of granisetron hydrochloride). Granisetron is a white to off-white solid with the molecular formula C18H24N4O·HCl and a molecular weight of 348.87 g/mol.
Inactive Ingredients (Excipients)
- Citric acid monohydrate — used as a buffering agent to maintain the pH of the solution within an acceptable range for intravenous administration.
- Hydrochloric acid — used for pH adjustment to ensure the solution is within the target pH range (approximately 4.0-6.0).
- Sodium chloride — used to adjust the tonicity (osmolarity) of the solution, making it compatible with blood and body fluids.
- Water for injections — the pharmaceutical-grade solvent that forms the base of the solution.
- Sodium hydroxide — used for pH adjustment as needed during manufacturing.
Appearance and Packaging
Granisetron Fresenius Kabi is a clear, colourless solution free from visible particles. Before administration, the solution should be visually inspected. Do not use it if it appears discoloured or contains any particulate matter.
The product is available in clear glass ampoules in the following presentations:
- 1 ml ampoules (containing 1 mg granisetron) — packs of 5 or 10 ampoules
- 3 ml ampoules (containing 3 mg granisetron) — packs of 5 or 10 ampoules
Not all pack sizes may be marketed in all countries. The ampoules are for single use only; any remaining solution after opening should be discarded in accordance with local pharmaceutical waste disposal regulations.
Frequently Asked Questions About Granisetron Fresenius Kabi
Granisetron Fresenius Kabi is used to prevent and treat nausea and vomiting caused by chemotherapy (cancer treatment with cytotoxic drugs), radiotherapy (radiation treatment for cancer), and surgery. It belongs to a group of medicines called 5-HT3 receptor antagonists that block the action of serotonin, a chemical that triggers the vomiting reflex. It is given as an intravenous injection or infusion by a healthcare professional and is approved for adults and children aged 2 years and older for chemotherapy-related indications.
When given intravenously, granisetron begins to take effect within minutes. Its onset of action is rapid because the drug is delivered directly into the bloodstream. For preventive use, it is administered before chemotherapy, radiotherapy, or surgery to ensure therapeutic levels are present when the emetogenic stimulus occurs. The antiemetic effect typically lasts for up to 24 hours after a single dose, although individual responses may vary.
There is limited clinical data on the use of granisetron in pregnant women. Animal studies have not shown direct harmful effects on the developing foetus at clinically relevant doses. However, as a precautionary measure, granisetron should only be used during pregnancy when the potential benefit to the mother justifies the potential risk to the unborn child. Your oncologist and obstetrician will make this decision together based on your specific circumstances and the urgency of your cancer treatment.
Both granisetron and ondansetron are 5-HT3 receptor antagonists used to prevent chemotherapy-induced nausea and vomiting, and they have broadly similar efficacy. However, there are some pharmacological differences. Granisetron has a longer half-life (approximately 9 hours versus 3-5 hours for ondansetron) and higher receptor binding affinity. Some clinical studies suggest that granisetron may be particularly effective for delayed nausea and vomiting. The choice between the two is often based on clinical experience, local availability, and individual patient response. Both are included in international antiemetic guidelines as equivalent options.
Before receiving granisetron, inform your doctor about: any allergies to granisetron or other 5-HT3 antagonists; any heart problems or a history of irregular heart rhythms; if you are taking SSRIs (such as fluoxetine or sertraline), SNRIs (such as venlafaxine), or any other serotonergic medications; any liver or kidney problems; if you have electrolyte imbalances; if you are pregnant, planning to become pregnant, or breastfeeding; and all other medications you are currently taking, including over-the-counter medicines and herbal supplements.
Yes, Granisetron Fresenius Kabi is approved for use in children aged 2 years and older for the prevention and treatment of chemotherapy- and radiotherapy-induced nausea and vomiting. The dose is calculated based on the child's body weight (10-40 micrograms per kilogram). However, it is not approved for post-operative nausea and vomiting in children. The medication is diluted and administered as an intravenous infusion over 5 minutes by a healthcare professional experienced in paediatric care.
References
This article is based on the following peer-reviewed sources and international medical guidelines. All claims are supported by Level 1A evidence where available.
- Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of Oncology. 2016;27(suppl 5):v119-v133. doi:10.1093/annonc/mdw270
- Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296
- European Medicines Agency (EMA). Granisetron Summary of Product Characteristics (SmPC). EMA Medicines Database. Accessed January 2026.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- Aapro M, Jordan K, Feyer P. Pathophysiology of Chemotherapy-Induced Nausea and Vomiting. In: Prevention of Nausea and Vomiting in Cancer Patients. Springer; 2015:1-12.
- Navari RM, Aapro M. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. New England Journal of Medicine. 2016;374(14):1356-1367. doi:10.1056/NEJMra1515442
- British National Formulary (BNF). Granisetron. NICE Evidence Services. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). Granisetron Hydrochloride Injection Prescribing Information. FDA Drug Database. Accessed January 2026.
- Multinational Association of Supportive Care in Cancer (MASCC). MASCC/ESMO Antiemetic Guidelines 2023. MASCC Antiemetic Tool. Accessed January 2026.
- Fresenius Kabi. Granisetron Fresenius Kabi 1 mg/ml Solution for Injection – Patient Information Leaflet. Last revised January 2022.
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising specialists in clinical pharmacology, oncology, and internal medicine. Our editorial process follows the GRADE evidence framework and adheres to international medical publishing standards.
Content authored by licensed physicians with expertise in clinical pharmacology and oncology supportive care, following WHO, EMA, FDA, and MASCC/ESMO guidelines.
Independently reviewed by the iMedic Medical Review Board for accuracy, completeness, and adherence to current evidence-based guidelines. Last reviewed: January 2026.
Evidence Level 1A based on systematic reviews and meta-analyses. GRADE framework applied. No conflicts of interest. No pharmaceutical industry funding.
Content reviewed for WCAG 2.2 Level AAA compliance. Optimized for screen readers, keyboard navigation, and assistive technology. 7:1 colour contrast ratio maintained throughout.